| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Consolidated net income | 487,900 | 326,400 | 133,800 | 433,900 |
| Depreciation and amortization | 540,800 | 355,700 | 176,400 | 506,900 |
| Stock-based compensation expense | 63,900 | 46,600 | 33,500 | 71,900 |
| Deferred income taxes | 29,600 | -7,300 | -3,000 | -45,200 |
| Gain on fair market value adjustment and gain on sale of equity investments | - | - | - | 0 |
| Gain on sale of equity investment | 800 | 800 | - | - |
| Accounts receivable, net | 45,600 | 69,000 | 55,000 | 47,800 |
| Other assets, current and long-term | 10,300 | 24,800 | 5,500 | 13,300 |
| Current and long term liabilities, excluding debt | 79,400 | -41,800 | -56,300 | 93,300 |
| Cash provided by operating activities | 1,144,900 | 585,000 | 223,900 | 999,700 |
| Capital expenditures | 351,400 | 229,400 | 107,200 | 392,600 |
| Acquisitions, net of cash acquired | - | - | - | 0 |
| Cash received from divestitures | 800 | 800 | - | 0 |
| Cash used in investing activities | -350,600 | -228,600 | -107,200 | -392,600 |
| Net short-term payments | 204,100 | 115,900 | 48,100 | 195,900 |
| Payments on long-term debt | 0 | 0 | 0 | 695,600 |
| Proceeds from issuance of long-term debt | 1,700 | - | - | 649,800 |
| Treasury stock purchases | 427,400 | 127,400 | - | - |
| Dividends paid to equifax shareholders | 172,000 | 110,500 | 48,500 | 144,800 |
| Distributions paid to noncontrolling interests | 6,200 | 4,200 | 0 | 4,400 |
| Proceeds from exercise of stock options and employee stock purchase plan | 38,100 | 24,400 | 12,300 | 67,500 |
| Payment of taxes related to settlement of equity awards | 13,600 | 13,200 | 11,500 | 16,400 |
| Debt issuance costs | 0 | - | - | 5,200 |
| Cash used in financing activities | -783,500 | -346,800 | -95,800 | -345,000 |
| Effect of foreign currency exchange rates on cash and cash equivalents | 8,300 | 9,500 | 4,400 | -10,700 |
| Increase in cash and cash equivalents | 19,100 | 19,100 | 25,300 | 251,400 |
| Cash and cash equivalents at beginning of period | 169,900 | 169,900 | 169,900 | 216,800 |
| Cash and cash equivalents at end of period | 189,000 | 189,000 | 195,200 | 468,200 |
EQUIFAX INC (EFX)
EQUIFAX INC (EFX)